Cardiometabolic risks in PCOS: a review of the current state of knowledge

Simple item page
dc.contributor.authorKakoly, N.S.
dc.contributor.authorMoran, L.J.
dc.contributor.authorTeede, H.J.
dc.contributor.authorJoham, A.E.
dc.date.issued2019
dc.descriptionPublished online: 15 Dec 2018
dc.description.abstractIntroduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 18% women of reproductive age. It is associated with a range of metabolic, reproductive, and psychological features. Current evidence indicates a role of PCOS in the development of metabolic and increased cardiovascular risk factors (CVRF) with implications for compromised cardiovascular endpoint disease, which may have a considerable impact on health and health care costs. Areas covered: Existing studies examining long-term cardiometabolic health in PCOS are heterogeneous with inconsistent findings. In the current review, we aim to explore and critically review retrospective, prospective, meta-analysis and review articles relating to PCOS on cardiometabolic risk factors and clinical consequences to summarize the evidence, note evidence gaps, and suggest implications for future research. Expert commentary: Although there is an established association between PCOS and metabolic health, implications on cardiac health are more uncertain with associations observed for CVRF and subclinical disease, yet limited and conflicting data on actual cardiovascular endpoints. There is a lack of population-based long-term studies examining cardiometabolic morbidity and mortality in PCOS with a need for further research to progress toward a better understanding of the long-term cardiometabolic impacts in women with PCOS.
dc.description.statementofresponsibilityNS Kakoly, LJ Moran, HJ Teede, AE Joham
dc.identifier.citationExpert Review of Endocrinology and Metabolism, 2019; 14(1):23-33
dc.identifier.doi10.1080/17446651.2019.1556094
dc.identifier.issn1744-6651
dc.identifier.issn1744-8417
dc.identifier.orcidMoran, L.J. [0000-0001-5772-6484]
dc.identifier.orcidTeede, H.J. [0000-0001-7609-577X]
dc.identifier.urihttps://hdl.handle.net/2440/140212
dc.language.isoen
dc.publisherTaylor and Francis
dc.relation.grantNHMRC
dc.rights© 2019 Informa UK Limited, trading as Taylor & Francis Group
dc.source.urihttps://doi.org/10.1080/17446651.2019.1556094
dc.subjectCardiovascular disease
dc.subjectinsulin resistance
dc.subjectmetabolic syndrome
dc.subjectobesity
dc.subjectpolycystic ovary syndrome
dc.subjecttype 2 diabetes
dc.subject.meshHumans
dc.subject.meshPolycystic Ovary Syndrome
dc.subject.meshCardiovascular Diseases
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshInsulin Resistance
dc.subject.meshObesity
dc.subject.meshRisk Factors
dc.subject.meshRetrospective Studies
dc.subject.meshProspective Studies
dc.subject.meshMiddle Aged
dc.subject.meshHealth Care Costs
dc.subject.meshFemale
dc.subject.meshDyslipidemias
dc.subject.meshMetabolic Syndrome
dc.titleCardiometabolic risks in PCOS: a review of the current state of knowledge
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Obstetrics and Gynaecology publications